Medicare Enrolled

Dr. Patricia Mikes, M.D.

Pulmonary Disease · Hinsdale, IL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
911 N ELM ST STE 328, Hinsdale, IL 60521
6302222951
In practice since 2006 (20 years)
NPI: 1255381877 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mikes from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mikes? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mikes

Dr. Patricia Mikes is a pulmonary disease specialist in Hinsdale, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mikes performed 1,194 Medicare services across 938 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mikes received a total of $176,584 from 19 pharmaceutical and/or device companies across 315 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mikes is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 35% volume in IL $176,584 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,194
Medicare services
Top 35% in IL for pulmonary disease
938
Unique beneficiaries
$78
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~60 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
203 $30 $136
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
196 $147 $245
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
171 $93 $185
New patient office visit, complex (60-74 min) 149 $167 $357
Prolonged office E/M service, first 15 minutes
This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service.
121 $26 $58
Breathing device use evaluation
An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling.
85 $14 $20
Exercise-induced bronchospasm test
A test used to check for exercise-induced bronchospasm, which is a narrowing of the lung airways triggered by physical activity.
60 $72 $93
Levalbuterol inhalation solution, 0.5 mg
A 0.5 mg unit dose of FDA-approved levalbuterol inhalation solution administered via durable medical equipment.
54 $0 $5
Exercise-induced lung stress test
A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising.
31 $28 $91
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
21 $64 $122
Lung volume test using sensors
A test that measures the amount of air in the lungs using sensors.
20 $45 $71
Pulmonary gas exchange test
A test to examine how well the lungs exchange gases.
20 $47 $69
Telephone medical discussion, 21-30 minutes
A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone.
19 $104 $250
Lung volume measurement test
A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs.
16 $13 $16
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
15 $108 $303
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
13 $68 $175
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$176,584
Total received (2018-2024)
Avg $25,226/year across 7 years
Top 5% in IL for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
19
Companies
315
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$168,663 (95.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$6,030 (3.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,891 (1.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$79,458
2023
$34,609
2022
$22,691
2021
$8,031
2020
$3,065
2019
$25,580
2018
$3,150

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$66,815
AstraZeneca Pharmaceuticals LP
$7,566
Regeneron Healthcare Solutions, Inc.
$4,563
GlaxoSmithKline, LLC.
$240
ANI Pharmaceuticals, Inc.
$57
Insmed, Inc.
$55
Amgen Inc.
$48
Philips North America LLC
$27
HARMONY BIOSCIENCES LLC
$25
Mallinckrodt Hospital Products Inc.
$24
Axsome Therapeutics, Inc.
$22
Mylan Specialty L.P.
$16
Top 3 companies account for 99.4% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$90,123
Regeneron Healthcare Solutions, Inc.
$53,253
AstraZeneca Pharmaceuticals LP
$25,648
Amgen Inc.
$5,953
GlaxoSmithKline, LLC.
$813
Novartis Pharmaceuticals Corporation
$305
Insmed, Inc.
$77
Genentech USA, Inc.
$62
Actelion Pharmaceuticals US, Inc.
$59
ANI Pharmaceuticals, Inc.
$57
Sunovion Pharmaceuticals Inc.
$42
Takeda Pharmaceuticals U.S.A., Inc.
$35
Philips North America LLC
$27
HARMONY BIOSCIENCES LLC
$25
Mallinckrodt Hospital Products Inc.
$24
Boehringer Ingelheim Pharmaceuticals, Inc.
$23
Axsome Therapeutics, Inc.
$22
Inspire Medical Systems, Inc.
$19
Mylan Specialty L.P.
$16
Top 3 companies account for 95.7% of all-time payments
Associated products mentioned in payments ›
(AK6) Vest Therapy · ACTHAR · AIRSUPRA · ANORO · Arikayce · BREO · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dexilant · Esbriet · FASENRA · INSPIRE · LONHALA MAGNAIR · NUCALA · OFEV · PURIFIED CORTROPHIN GEL · SYMBICORT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · Trintellix · Utibron · WAKIX · XOLAIR · Xolair · YUPELRI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for pulmonary disease in IL.

Looking for a pulmonary disease specialist in Hinsdale?
Compare pulmonary diseases in the Hinsdale area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
248
Per 100K population
26.7
County median income
$110,502
Nearest hospital
UCHICAGO MEDICINE ADVENTHEALTH HINSDALE
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Mikes is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 5% of IL peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Mikes experienced with spirometry test before and after medication?
Based on Medicare claims data, Dr. Mikes performed 203 spirometry test before and after medication services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mikes receive payments from pharmaceutical companies?
Yes. Dr. Mikes received a total of $176,584 from 19 companies across 315 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mikes's costs compare to other pulmonary diseases in Hinsdale?
Dr. Mikes's average Medicare payment per service is $78. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mikes) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →